Bodur, H. Et Al. 2022. Where we are in treat to target era? Predictive factors for remission and drug switching in patients with axial spondyloarthritis: a real-life evidence from BioStaR nationwide registry. CLINICAL RHEUMATOLOGY , vol.41 , 2053-2063.

Bodur, H., Yurdakul, F. G., ATAMAN, Ş., Cay, H. F., GÜRER, G., ÇAPKIN, E., ... SEZER, İ.(2022). Where we are in treat to target era? Predictive factors for remission and drug switching in patients with axial spondyloarthritis: a real-life evidence from BioStaR nationwide registry. CLINICAL RHEUMATOLOGY , vol.41, 2053-2063.

Bodur, Hatice Et Al. "Where we are in treat to target era? Predictive factors for remission and drug switching in patients with axial spondyloarthritis: a real-life evidence from BioStaR nationwide registry," CLINICAL RHEUMATOLOGY , vol.41, 2053-2063, 2022

Bodur, Hatice Et Al. "Where we are in treat to target era? Predictive factors for remission and drug switching in patients with axial spondyloarthritis: a real-life evidence from BioStaR nationwide registry." CLINICAL RHEUMATOLOGY , vol.41, pp.2053-2063, 2022

Bodur, H. Et Al. (2022) . "Where we are in treat to target era? Predictive factors for remission and drug switching in patients with axial spondyloarthritis: a real-life evidence from BioStaR nationwide registry." CLINICAL RHEUMATOLOGY , vol.41, pp.2053-2063.

@article{article, author={Hatice Bodur Et Al. }, title={Where we are in treat to target era? Predictive factors for remission and drug switching in patients with axial spondyloarthritis: a real-life evidence from BioStaR nationwide registry}, journal={CLINICAL RHEUMATOLOGY}, year=2022, pages={2053-2063} }